Stock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates

Stock Track

2024-11-05

Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.

For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.

The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1179911745"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179911745\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1179911745?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 05:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179911745","market":"us","top_or_hot":-1,"title":"Stock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates","media":"Stock Track","content":"<p>Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.</p>\n\n<p>For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.</p>\n\n<p>The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-05 05:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.</p>\n\n<p>For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.</p>\n\n<p>The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1179911745","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179911745","pubTimestamp":1730756542,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Castle Biosciences, Inc.  stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.For the quarter ended September 30, 2024, the company reported earnings per share  of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.The s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Castle Biosciences第三季度盈利预期大幅上涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1},"content_text":"Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.\nFor the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.\nThe strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}